Advice

in the absence of a submission from the holder of the marketing authorisation:

perampanel (Fycompa®) is not recommended for use within NHSScotland.

Indication under review: for the adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download detailed advice351KB (PDF)

Download

Medicine details

Medicine name:
perampanel (Fycompa)
SMC ID:
SMC2218
Indication:

For the adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy.

Pharmaceutical company
Eisai Ltd
BNF chapter
Central nervous system
Submission type
Non submission
Status
Not recommended
Date advice published:
12 August 2019